(R)-8-(4-(bis(4-chlorophenyl)methyl)-3-methylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2,7-dicarbonitrile

ID: ALA4647083

Chembl Id: CHEMBL4647083

PubChem CID: 146529410

Max Phase: Preclinical

Molecular Formula: C29H24Cl2N6O

Molecular Weight: 543.46

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1CN(c2c(C#N)c(=O)n(C)c3ccc(C#N)nc23)CCN1C(c1ccc(Cl)cc1)c1ccc(Cl)cc1

Standard InChI:  InChI=1S/C29H24Cl2N6O/c1-18-17-36(28-24(16-33)29(38)35(2)25-12-11-23(15-32)34-26(25)28)13-14-37(18)27(19-3-7-21(30)8-4-19)20-5-9-22(31)10-6-20/h3-12,18,27H,13-14,17H2,1-2H3/t18-/m1/s1

Standard InChI Key:  SDZJBPNDMVKIRN-GOSISDBHSA-N

Alternative Forms

  1. Parent:

    ALA4647083

    ---

Associated Targets(Human)

DGKA Tbio Diacylglycerol kinase alpha (73 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DGKZ Tchem Diacylglycerol kinase zeta (13 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DGKA Tbio Diacylglycerol kinase alpha/zeta (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 543.46Molecular Weight (Monoisotopic): 542.1389AlogP: 5.28#Rotatable Bonds: 4
Polar Surface Area: 88.95Molecular Species: NEUTRALHBA: 7HBD:
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 6.05CX LogP: 5.09CX LogD: 5.07
Aromatic Rings: 4Heavy Atoms: 38QED Weighted: 0.35Np Likeness Score: -0.94

References

1. Abdel-Magid AF..  (2020)  Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta.,  11  (6): [PMID:32550982] [10.1021/acsmedchemlett.0c00118]

Source